Overview
Kidney cancer is a heterogenous disease. This book covers: surgical approaches which are becoming the standard, i.e., nephon sparing, laporascopic, minimally invasive techniques; new staging and prognostic capabilities; evolving therapeutic options including, cell based vaccine, gene and antibody therapy; and molecular genetics which allow for a better understanding of the various types of kidney cancer. ""Kidney Cancer"" is a comprehensive review covering present and future surgical approaches, staging and prognostic factors, currently accepted and future plans for prevention, diagnosis and treatment. Contributing authors to this book are internationally recognized specialists in this disease. This book should be useful to the specialist (oncologist and urologist), primary care physicians, patients and family members dealing with kidney cancer.
Full Product Details
Author: Robert A. Figlin
Publisher: Springer-Verlag New York Inc.
Imprint: Springer-Verlag New York Inc.
Edition: 2003 ed.
Volume: 116
Dimensions:
Width: 15.50cm
, Height: 1.50cm
, Length: 23.50cm
Weight: 1.200kg
ISBN: 9781402074578
ISBN 10: 1402074573
Pages: 246
Publication Date: 31 October 2003
Audience:
College/higher education
,
Professional and scholarly
,
Postgraduate, Research & Scholarly
,
Professional & Vocational
Format: Hardback
Publisher's Status: Active
Availability: In Print
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.
Reviews
This text provides a comprehensive overview of kidney cancer. Investigative leaders in the field discuss the genetic, biologic and clinical manifestations of the disease. Modern therapy is reviewed with commentary on future alternatives and novel compounds. (Steven T. Rosen, M.D., Series Editor)
This text provides a comprehensive overview of kidney cancer. Investigative leaders in the field discuss the genetic, biologic and clinical manifestations of the disease. Modern therapy is reviewed with commentary on future alternatives and novel compounds. <br>(Steven T. Rosen, M.D., Series Editor)
Author Information
Robert A. Figlin, Professor of Medicine, Urology, Departments of Medicine and Urology, Division of Hematology/Oncology, University of California, Los Angeles School of Medicine, USA, holds the Henry Alvin and Carrie L. Meinhardt Chair in Urologic Oncology. He serves as Medical Director of the Thoracic and Genitourinary Oncology Program. He is a Senior Clinical Investigator in areas of genitourinary and thoracic oncology and has served as Principal Investigator on Phase I, II, and III trials. He serves as Chairman of the UCLA Medical Institutional Review Board and as a member of the UCLA Human Research Policy Board.
